<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - [REDACTED]</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Allergies</a></li><li><a href="#id2">REASON FOR VISIT</a></li><li><a href="#id3">Medications</a></li><li><a href="#id4">Vital Signs</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Assessments</a></li><li><a href="#id7">Plan Of Treatment</a></li><li><a href="#id8">Procedure Notes</a></li><li><a href="#id9">History and Physical Notes</a></li><li><a href="#id10">Progress Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Allergies</a></h3><div><table width="100%" border="1"><thead><tr><th>Allergen (clinical drug ingredient)</th><th>Drug/Non Drug Allergy documented on EMR</th><th>Reaction</th><th>Allergy Type</th><th>Onset Date</th><th>Status</th></tr></thead><tbody><tr><td ID="allergy1"/><td>Penicillin</td><td ID="reaction1">Unknown</td><td>Drug Allergy</td><td/><td>Active</td></tr></tbody></table></div><h3><a name="id2" href="#toc">REASON FOR VISIT</a></h3><div>IV Leqembi</div><h3><a name="id3" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Ondansetron HCl 4 MG Tablet</td><td ID="instruction1"><p>1 tablet Orally every 8 hours; Duration: 30 days</p><p>As needed</p></td><td/><td>[REDACTED]</td><td/><td>Active</td></tr><tr><td ID="medication2">Donepezil HCl 5 MG Tablet</td><td ID="instruction2">1 tablet at bedtime Orally Once a day; Duration: 30 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication3">Memantine HCl 5 MG Tablet</td><td ID="instruction3">TAKE 1 TABLET BY MOUTH TWICE DAILY; Duration: 30</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">Alendronate Sodium 70 MG Tablet</td><td ID="instruction4">TAKE 1 TABLET BY MOUTH 1 TIME A WEEK 30 MINUTES BEFORE FIRST FOOD OR BEVERAGE OR MEDICINE OF THE DAY WITH WATER Oral; Duration: 84 Days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">Losartan Potassium 50 MG Tablet</td><td ID="instruction5">TAKE 1 TABLET BY MOUTH DAILY Oral; Duration: 90 Days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication6">Escitalopram Oxalate 20 MG Tablet</td><td ID="instruction6">TAKE 1 TABLET BY MOUTH EVERY DAY Oral; Duration: 90 Days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication7">Pravastatin Sodium 20 MG Tablet</td><td ID="instruction7">TAKE 1 TABLET BY MOUTH DAILY Oral; Duration: 90 Days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication8">Omeprazole 40 MG Capsule Delayed Release</td><td ID="instruction8">TAKE 1 CAPSULE BY MOUTH DAILY Oral; Duration: 90 Days</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Vital Signs</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Height</th><td>60 in</td><td>[REDACTED]</td></tr><tr><th ID="vital2">Height-cm</th><td>152.4 cm</td><td>[REDACTED]</td></tr><tr><td colspan="3"><span class="content_span">See Flowsheet</span></td></tr></tbody></table></div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>Neuroscience Consultants 25-Infusion</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Other Alzheimer's disease G30.8</td></tr></tbody></table></div><h3><a name="id6" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th><th>Section Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>Other Alzheimer's disease (ICD-10 - G30.8)</td><td/><td/><td/><td/></tr></tbody></table></div><h3><a name="id7" href="#toc">Plan Of Treatment</a></h3><div><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="nextAppt">Follow Up: [REDACTED], Reason: </td></tr><tr><td ID="futureAppt1">Provider Name:[REDACTED], [REDACTED] 10:30:00 AM, [REDACTED][REDACTED], [REDACTED]</td></tr><tr><td ID="futureAppt2">Provider Name:[REDACTED], [REDACTED] 11:15:00 AM, [REDACTED][REDACTED], [REDACTED]</td></tr></tbody></table></div><h3><a name="id8" href="#toc">Procedure Notes</a></h3><div><ul><li><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th></tr></thead><tbody><tr><td rowspan="19">IV Administration</td><td>Name:</td><td colspan="2">Leqembi</td></tr><tr><td>Consent:</td><td colspan="2">A written consent was obtained from the patient</td></tr><tr><td>Time infusion medication mixed:</td><td colspan="2">1236</td></tr><tr><td>Time infusion started:</td><td colspan="2">1237</td></tr><tr><td>Batch Number/Lot #:</td><td colspan="2">500mg Lot #726884 200mg Lot #735957</td></tr><tr><td>Expiry Date:</td><td colspan="2">500mg Exp: 10/2026 200mg Exp: 08/2027</td></tr><tr><td>Site of IV:</td><td colspan="2">L FA- 22G- secured and flushed with 3ml 0.9% NS</td></tr><tr><td>Given By:</td><td colspan="2">[REDACTED]</td></tr><tr><td>Discharge:</td><td colspan="2">Post infusion assessment, patient denies any changes from baseline, denies having any headaches, dizziness, changes in thinking. Post discharge instructions given</td></tr><tr><td>Monitored By:</td><td colspan="2">RN monitored the patient pre and post treatment</td></tr><tr><td>Infusion Stop Time:</td><td colspan="2">1337</td></tr><tr><td>Pre-medications:</td><td colspan="2">None</td></tr><tr><td>If stopped prematurely why:</td><td colspan="2">_____</td></tr><tr><td>Adverse reactions:</td><td colspan="2">0 SAE noted_</td></tr><tr><td>Clinical notes:</td><td colspan="2">Patient arrived to the infusion center walking on her own accompanied by her sister. Covid-19 questionnaire completed. Consent was signed for Leqembi infusion and kept in patient's chart. Labs were reviewed. No signs or symptoms of active infection noted at this time. [REDACTED] weight is 70kg. Medication education was reinforced with the patient. First set of vital signs were taken at 1230 (see flowsheet). PIV access obtained on the Left FA, 22G, flushed with 10cc 0.9% NaCl at 1235 x 1 attempt. Brisk blood return noted. No redness pain or swelling to site. Leqembi 700mg (BB) was mixed in a 0.9% NaCl 250cc stock bag at 1236. Leqembi infusion began at 1237. Pt's V/S within normal limits. Leqembi infusion finished at 1337. Patient was observed per protocol. PIV access removed with minimal bleeding at the site, catheter tip intact. Prior to removing IV line was flushed with 10cc of 0.9% sodium chloride prefilled syringe. Brisk blood return with no redness pain or swelling to site. Post-infusion education was given; Patient educated on signs/symptoms to report to MD and were advised to call 911 for any shortness of breath, chest pain or difficulty swallowing. Advised to monitor for headache and to report immediately especially if patient is not prone to headaches. Reinforced MRI schedule with patient and noted on FCN Discharge Instruction Sheet. Pt and spouse verbalized good understanding of the instructions. Patient left facility in stable condition walking on her own with her sister.</td></tr><tr><td>Total number of mg infused:</td><td colspan="2">700mg</td></tr><tr><td>Total number of mg wasted:</td><td colspan="2">0mg</td></tr><tr><td>Total Number of Vial Sizes Used:</td><td colspan="2">2 vials</td></tr><tr><td>Registry Submission Number:</td><td colspan="2">17857</td></tr></tbody></table><br/></li></ul></div><h3><a name="id9" href="#toc">History and Physical Notes</a></h3><div><ul><li><p>HPI (History of Present Illness)</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th><th>Category Notes</th></tr></thead><tbody><tr><td rowspan="10">IV Infusion</td><td rowspan="4">Since last infusion Has there been significant change in:</td><td>Walking: No</td><td/><td rowspan="10"/></tr><tr><td>Mental Function: No</td><td/></tr><tr><td>Balance/ Coordination: No</td><td/></tr><tr><td>Vision: No</td><td/></tr><tr><td>Has there been any infection in the last four weeks?</td><td colspan="2">No</td></tr><tr><td>Date of First Dose</td><td>:: [REDACTED]</td><td/></tr><tr><td>Date and Dose Number:</td><td colspan="2">[REDACTED] Leqembi IV 700mg 70kg Infusion #6</td></tr><tr><td>Consent:</td><td colspan="2">A written consent was obtained from the patient</td></tr><tr><td>Verification of ID:</td><td colspan="2">Yes</td></tr><tr><td>Verification of Medication to be administered:</td><td colspan="2">Yes</td></tr></tbody></table><br/></li></ul></div><h3><a name="id10" href="#toc">Progress Notes</a></h3><div><ul><li><table width="99%" border="0" cellspacing="0" cellpadding="0"><thead><tr><td><content>[REDACTED] <span class="bold">DOB:</span> [REDACTED] ([REDACTED] F) <span class="bold">Acc No.</span> 1532024 <span class="bold">DOS:</span> [REDACTED]</content></td></tr></thead><tbody><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td align="right" colspan="2"><span class="bold">IV-Leqembi-BB</span></td></tr><tr><td align="left"><span class="bold">Patient: </span>[REDACTED]<br/><span class="bold">Account Number: </span>1532024</td><td align="right"><span class="bold">Provider: </span>[REDACTED], MD</td></tr><tr><td align="left"/></tr><tr><td align="left"><span class="bold">DOB: </span>[REDACTED]<span class="bold">   Age: </span>79 Y<span class="bold">   Sex: </span>Female</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td><span class="bold">Phone: </span>[REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Address: </span>[REDACTED][REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Pcp: </span>[REDACTED], MD </td></tr></tbody></table></li></ul><br/><content><span class="bold">Subjective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Chief Complaints:</span></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td>   IV Leqembi</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">HPI: </span><br/>   <span class="Underline">IV Infusion</span>: <br/>      Consent: A written consent was obtained from the patient. <br/>      Verification of ID: Yes. <br/>      Verification of Medication to be administered: Yes. <br/>      Since last infusion Has there been significant change in: <br/>         Walking <span class="italics">No</span><br/>         Mental Function <span class="italics">No</span><br/>         Balance/ Coordination <span class="italics">No</span><br/>         Vision <span class="italics">No</span><br/>      Has there been any infection in the last four weeks? No. <br/>      Date of First Dose <br/>         : <span class="italics">[REDACTED]</span><br/>      Date and Dose Number: <span class="bold">[REDACTED] Leqembi IV 700mg 70kg Infusion #6</span>. </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medical History:</span> <br/>Anxiety<br/>Back pain<br/>Gastric reflux<br/>Hypertension</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medications:</span> TakingPravastatin Sodium 20 MG Tablet TAKE 1 TABLET BY MOUTH DAILY Oral  Omeprazole 40 MG Capsule Delayed Release TAKE 1 CAPSULE BY MOUTH DAILY Oral  Escitalopram Oxalate 20 MG Tablet TAKE 1 TABLET BY MOUTH EVERY DAY Oral  Alendronate Sodium 70 MG Tablet TAKE 1 TABLET BY MOUTH 1 TIME A WEEK 30 MINUTES BEFORE FIRST FOOD OR BEVERAGE OR MEDICINE OF THE DAY WITH WATER Oral  Losartan Potassium 50 MG Tablet TAKE 1 TABLET BY MOUTH DAILY Oral  Ondansetron HCl 4 MG Tablet 1 tablet Orally every 8 hours As neededDonepezil HCl 5 MG Tablet 1 tablet at bedtime Orally Once a day Memantine HCl 5 MG Tablet TAKE 1 TABLET BY MOUTH TWICE DAILY   Taking Pravastatin Sodium 20 MG Tablet TAKE 1 TABLET BY MOUTH DAILY Oral  Taking Omeprazole 40 MG Capsule Delayed Release TAKE 1 CAPSULE BY MOUTH DAILY Oral  Taking Escitalopram Oxalate 20 MG Tablet TAKE 1 TABLET BY MOUTH EVERY DAY Oral  Taking Alendronate Sodium 70 MG Tablet TAKE 1 TABLET BY MOUTH 1 TIME A WEEK 30 MINUTES BEFORE FIRST FOOD OR BEVERAGE OR MEDICINE OF THE DAY WITH WATER Oral  Taking Losartan Potassium 50 MG Tablet TAKE 1 TABLET BY MOUTH DAILY Oral  Taking Ondansetron HCl 4 MG Tablet 1 tablet Orally every 8 hours As neededTaking Donepezil HCl 5 MG Tablet 1 tablet at bedtime Orally Once a day Taking Memantine HCl 5 MG Tablet TAKE 1 TABLET BY MOUTH TWICE DAILY   </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Allergies:</span> PenicillinyesAllergies Verified.</td></tr></tbody></table></li></ul><br/><content><span class="bold">Objective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Vitals:</span> Ht:: 60 in, Ht-cm: 152.4 cm.<br/><span class="content_span">See Flowsheet</span>.</td></tr></tbody></table></li></ul><br/><br/><content><span class="bold">Assessment:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Assessment: </span></td></tr><tr><td/></tr><tr><td>1. Other Alzheimer's disease - G30.8 (Primary)   </td></tr></tbody></table></li></ul><br/><content><span class="bold">Plan:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Procedures:</span> <br/>   <span class="Underline">IV Administration</span>: <br/>      Name: Leqembi. <br/>      Total Number of Vial Sizes Used: 2 vials. <br/>      Registry Submission Number: 17857. <br/>      Pre-medications: None. <br/>      Total number of mg infused: 700mg. <br/>      Total number of mg wasted: 0mg. <br/>      Consent: A written consent was obtained from the patient. <br/>      Time infusion medication mixed: 1236. <br/>      Time infusion started: 1237. <br/>      Batch Number/Lot #: 500mg Lot #726884<br/>200mg Lot #735957. <br/>      Expiry Date: 500mg Exp: 10/2026<br/>200mg Exp: 08/2027. <br/>      Site of IV: L FA- 22G- secured and flushed with 3ml 0.9% NS. <br/>      If stopped prematurely why: _____. <br/>      Infusion Stop Time: 1337. <br/>      Adverse reactions: 0 SAE noted_. <br/>      Clinical notes: Patient arrived to the infusion center walking on her own accompanied by her sister. Covid-19 questionnaire completed. Consent was signed for Leqembi infusion and kept in patient's chart. Labs were reviewed. No signs or symptoms of active infection noted at this time.<span class="bold"> [REDACTED] weight is 70kg</span>. Medication education was reinforced with the patient. First set of vital signs were taken at 1230 (see flowsheet). PIV access obtained on the Left FA, 22G, flushed with 10cc 0.9% NaCl at 1235 x 1 attempt. Brisk blood return noted. No redness pain or swelling to site. Leqembi 700mg (BB) was mixed in a 0.9% NaCl 250cc stock bag at 1236. Leqembi infusion began at 1237. Pt's V/S within normal limits. Leqembi infusion finished at 1337. Patient was observed per protocol. PIV access removed with minimal bleeding at the site, catheter tip intact. Prior to removing IV line was flushed with 10cc of 0.9% sodium chloride prefilled syringe. Brisk blood return with no redness pain or swelling to site. Post-infusion education was given; Patient educated on signs/symptoms to report to MD and were advised to call 911 for any shortness of breath, chest pain or difficulty swallowing. Advised to monitor for headache and to report immediately especially if patient is not prone to headaches. Reinforced MRI schedule with patient and noted on FCN Discharge Instruction Sheet. Pt and spouse verbalized good understanding of the instructions. Patient left facility in stable condition walking on her own with her sister. <br/>      Given By: [REDACTED], RN. <br/>      Discharge: Post infusion assessment, patient denies any changes from baseline, denies having any headaches, dizziness, changes in thinking. Post discharge instructions given. <br/>      Monitored By: RN monitored the patient pre and post treatment.   <br/>      </td></tr><tr><td/></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Follow Up:</span> [REDACTED]</td></tr></tbody></table></li></ul><br/><content><span class="bold">Billing  Information:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content><span class="bold">Procedure Codes:</span></content> </td></tr></tbody></table></li></ul><br/><ul><li><table width="100%" border="0"><tbody><tr><td/></tr><tr><td valign="top"/></tr><tr><td/></tr><tr><td/></tr><tr><td valign="top">Electronically signed by [REDACTED]   on [REDACTED] 01:39 PM EDT</td></tr><tr><td valign="top">Sign off status: Completed</td></tr><tr><td/></tr></tbody></table></li></ul><span class="content_span">true</span></td></tr></tbody><tbody><tr><td><br/><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td align="left"><span class="bold">Provider:</span> [REDACTED], MD</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td/><td align="right"><span class="content_span">Generated for Printing/Faxing/eTransmitting on: [REDACTED] 12:43 PM EDT</span></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></div><br/><br/>
</body></html>